|
Dear VRAN Members & Friends, A stunning new disclosure by journalist Cynthia Janak reveals that Gardasil (HPV) vaccine dramatically increases the risk of pre-cancerous cervical lesions if injected into girls/women who are already infected with the sero-types contained in the vaccine. Janak's excellent article, Gardasil-my error is the smoking gun , also highlights the accumulated adverse reactions, injuries and deaths associated with the new human papilloma virus vaccine aggressively marketed as a cervical cancer preventive and now being injected into thousands of Canadian and American girls. Long time VRAN member Susan Fletcher has launched a media campaign in her area (coastal British Columbia) by sending the following letter to media outlets. Attached to the letter is our letter to Dr. David Butler-Jones, Canada's Chief Medical Officer of Health. We urge you to take a similar action in your area. Please send this letter or a similar one along with VRAN's letter to Dr. Butler-Jones to media people in your area, as well as to the medical officer of health in charge of your health district. (Addressed to media outlets) A letter marked "URGENT" has been sent to Canada's Chief Officer of Public Health, Dr David Butler-Jones. It cites a document submitted to the US FDA in 2006. The document shows that the vaccine, 'Gardasil', increased the risk of cervical cancer by 44.6 % for females who, at the time of vaccination, were infected with the same strains of HPV as are used in the vaccine. HPV (human papillomavirus) is sexually transmitted. But skin-to-skin contact alone can also allow transfer. This means that no female can be absolutely certain they don't carry vaccine-strain HPV unless they have been tested for it using the latest highly sensitive and specific testing methods. School-based HPV vaccine programs are already in place in much of the country and the vaccine has also been recommended for females up to 26 yrs old. The letter, sent by Vaccination Risk Awareness Network Inc, asks for immediate attention to this matter. It states that all use of 'Gardasil' must be halted and that, henceforth, only females who can be accurately screened and found to be absent of HPV prior to vaccination should be considered candidates for receiving this vaccine. (Sign with your name and contact information) Reference: Dr David Butler-Jones URGENT! Gardasil vaccine may increase risk of cervical cancer. It has come to our attention that injection of Gardasil vaccine into females who are carrying vaccine-type HPV puts these females at risk of developing cervical cancer. A document submitted to the US FDA, written March 7, 2007 states: "A PCR-based HPV detection device with provision for accurate HPV genotyping is more urgently needed now because vaccination with GardasilTM of the women who are already sero-positive and PCR-positive for vaccine-relevant genotypes of HPV has been found to increase the risk of developing high-grade precancerous lesions by 44.6%, according to an FDA VRBPAC Background Document: GardasilTM HPV Quadrivalent Vaccine . May 18, 2006 VRBPAC Meeting." [my emphasis] (The above quote is taken from PDF pg 9 of 68, document pg 8 of the following: [PDF] In the section 'XII. Conclusions and summary' of the same article, last paragraph, is the following: "In a document submitted to the FDA by Merck & Co., Inc., it is recorded that injection of the HPV vaccine, GardasilTM, into women who are sero-positive and PCR-positive for the vaccine-related HPV genotypes increases the risk of developing high-grade intraepithelial lesions by 44.6%. As of to-date, there are no FDA approved PCR-based methods for HPV genotyping on the market in spite of the fact the PCR technology has been available for about 20 years. This petitioner urges the FDA to play a leadership role to guide the device manufacturers to introduce their most sensitive and most specific PCR-based IVDs to assist the sexually active women who are still considering immunization against HPV infections without inadvertently receiving a vaccine that is not only ineffective, but may augment the risk of developing a precancerous lesion in the cervix. �" [my emphasis] The following table from 'VRBPAC Background Document Gardasil� HPV Quadrivalent Vaccine May 18, 2006 VRBPAC Meeting' at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf showed decreased efficacy of -44.6% when GardasilTM was given to subjects who had vaccine-relevant HPV infections:
Needless to say, we are most concerned about this risk. Considering that school-based HPV vaccine programs are already in progress in much of the country; that, according to the NACI Statement on Human Papillomavirus Vaccine, pg 15, "27% of teens between the ages of 14 and 17 years reported being sexually active. Of these, 20% reported having had sexual activity by 15 years of age."; and that skin-to-skin contact alone can allow transfer of HPV � it is imperative that you halt any further use of Gardasil. Only girls and women who can be screened prior to vaccination should be allowed to receive this vaccine, and only then if highly sensitive and specific testing is used. We ask for your immediate attention to this matter. Sincerely, |
